1 de outubro de 2020

GlaxoSmithKline to Market Nicotine Vaccine

23 de novembro de 20091min

November 20, 2009
GlaxoSmithKline will invest up to a half-billion dollars for the right to market a nicotine vaccine being developed by Nabi Biopharmaceuticals, Reuters reported Nov. 16.
The pharmaceutical giant inked a deal that gives Nabi $40 million upfront to continue developing NicVAX, and Nabi potentially could receive more than $500 million from GlaxoSmithKline for the rights to market the drug worldwide and develop other versions of the vaccine.

Nabi recently received a $10-million grant from the National Institute on Drug Abuse for research on NicVAX, which triggers the immune system to attack nicotine molecules in the body.

Nabi’s stock rose sharply in value upon news of the GlaxoSmithKline deal.

 


Sobre a UNIAD

A Unidade de Pesquisa em álcool e Drogas (UNIAD) foi fundada em 1994 pelo Prof. Dr. Ronaldo Laranjeira e John Dunn, recém-chegados da Inglaterra. A criação contou, na época, com o apoio do Departamento de Psiquiatria da UNIFESP. Inicialmente (1994-1996) funcionou dentro do Complexo Hospital São Paulo, com o objetivo de atender funcionários dependentes.



Newsletter